Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print December 16, 2005, doi:10.1212/01.wnl.0000192258.32408.54)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
01.wnl.0000192258.32408.54v1
66/1_suppl_1/S123    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barohn, R. J.
Right arrow Articles by Mendell, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barohn, R. J.
Right arrow Articles by Mendell, J. R.
NEUROLOGY 2006;66:S123-S124
© 2006 American Academy of Neurology

Pilot trial of etanercept in the treatment of inclusion-body myositis

R. J. Barohn, MD, L. Herbelin, BS, J. T. Kissel, MD, W. King, PT, A. L. McVey, MD, D. S. Saperstein, MD and J. R. Mendell, MD

From the Department of Neurology (R.J.B., L.H., D.S.S.), University of Kansas Medical Center, Kansas City, KS; and the Department of Neurology (J.K., W.K., A.L.M., J.R.M.), Ohio State University, Columbus, OH.

address correspondence and reprint requests to Dr. Richard J. Barohn, Department of Neurology, University of Kansas Medical Center, 3599 Rainbow Blvd., MS # 2012, Kansas City, KS 66160; e-mail: rbarohn{at}kumc.edu

Inclusion-body myositis (IBM) is an inflammatory muscle disease that has proven resistant to treatment. Tumor necrosis factor molecules have been detected in muscle biopsies from patients with IBM. Etanercept is a TNF{alpha} receptor fusion protein that binds and inactivates tumor necrosis factor. Nine patients were treated with etanercept at a dose of 25 mg, two times a week for an average of 17 ± 6.1 months. Each patient was evaluated using quantitative strength testing. Their data were compared to two different control groups. The first control group consisted of patients who participated in trials of beta-interferon-1A and had received placebo. There was no significant difference. The second control group was a natural history cohort of IBM patients. There was no statistically significant difference between the treated group and the natural history group at 6 and 12 months when looking at elbow flexors, or 6 months when looking at hand grip. In the treated patients there was a small but significant improvement (p = 0.002) in handgrip at 12 months.

This article was previously published in electronic format as an Expedited E-Pub at www.neurology.org.

Disclosure: The authors report no conflicts of interest.

Received June 22, 2005. Accepted in final form October 14, 2005.

Please




This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.